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Abstract-A novel approach for the preparation of oligonucleotides carrying 
amino groups at the 3'-end is described. Several CPG supports having 
aminoalkyl groups and 3'-amino-2',3'-dideoxynucleosides linked through 
base-labile carbamate linkages such as 2-(2-nitrophenyl)ethoxycarbonyl 
and fluorenylmethoxycarbonyl were prepared using two different strategies. 
These supports are compatible to the standard solid phase phosphite-
triester methodology and yield oligonucleotides containing amino groups at 
the 3'-end. Several properties of the 3'-amino oligonucleotides, such as 
nuclease resistance, hybridization, and preparation of oligonucleotide 
conjugates are discussed. 
 
 
Introduction 
 
Modified oligonucleotides having amino groups at the 3'- and the 5'-
ends are useful intermediates for the preparation of conjugates carrying a 
large variety of functionalities including fluorochromes, biotin, intercalators, 
enzymes, modifiers of cellular uptake, and reactive groups (1). 
Furthermore, it has been shown that 3'-amine oligonucleotides have an 
increased nuclease resistance that makes them good candidates for 
antisense studies (2, 3). 
The introduction of amino groups at the 5'-end of oligonucleotides is 
performed with phosphoramidites derived from 5'-amino nucleosides or 
from aminoalcohols (1, 4). The introduction of amino groups at the 3'-end is 
more troublesome due to the need of special linker molecules to connect 
the desired amine to the solid support. These linker molecules should be 
stable to oligonucleotide synthesis conditions, but they should release the 
modified oligonucleotide during, after or before ammonia deprotection. The 
following linkers have been reported: (i) aminodiols such as 3-amino- 1,2-
propanediol (5), 2-aminobutyl-1,3-propanediol (6), N-(3-aminoprop-1-yl)-
N,N-bis(2-hydroxyethyl)amine (7), and 3,5-bis(hydroxymethyl)benzyl 
amine (8); (ii) phosphoramidate linkers (9,10); (iii) phthalimido linkers (3, 
11); (iv) glycolic and 4-hydroxybutyric esters (12); (v) 2, 2'-dithio-
ethoxycarbonyl derivatives (13) (vi) 2'- and 3'-O-alkylaminoribonucleotides 
(14).  Aminodiols are the most commonly used linkers for the preparation of 
3'-amino oligonucleotides. Some of these linkers are commercially available 
and are used for the preparation of oligonucleotide conjugates. 
 
Although base-labile carbamates such as fluorenylmethoxycarbonyl 
(FMOC) are commonly used for the protection of the amino groups in 
peptide synthesis, there is no description of similar groups for anchoring 
amino compounds such as 3'-amine oligonucleotides. The use of base-labile 
carbamates to anchor amine groups could eliminate the necessity of 
preparation of special trifunctional compounds and, in this way, facilitate 
the preparation of 3'-amine oligonucleotides. Also, the availability of 
polymeric base labile carbamates will open the possibility for the addition of 
different amine compounds at the 3'-end of oligonucleotides. As recently 
summarized by Manoharan (2) aliphatic amines at the 3'-end could have by 
themselves interesting properties, such as improved cellular uptake and 
enhanced stability to nuclease degradation. For these reasons, it will be 
interesting to have a fast and efficient method to prepare oligonucleotides 
having different amine compounds at the 3'-end. In this report, we describe 
the use of solid supports having the base labile 2-(2 
nitrophenyl)ethoxycarbonyl (NPEOC) (15) and FMOC (16) linkers for the 
preparation of 3'-amine oligonucleotides (Fig. 1). In order to test the new 
supports we have used aminoalcohols as model compounds of primary 
amino groups and 3'-amino- 2',3'-dideoxynucleosides as model compounds 
of secondary amino groups. 
 
Figure 1. Structure of NPEOC and FMOC carbamate linkages prepared in 
this work. 
 
 
Results 
 
Preparation of the amino derivatives 
Two types of amino derivatives have been selected to be introduced 
at the 3'-end of oligonucleotides: (1) amino alkyl derivatives such as 2-
aminoethanol, 3-aminopropanol, and 6-aminohexanol; and (2) 3'- amino 
2',3'-dideoxynucleosides (uridine and cytidine). In order to be used for 
oligonucleotide synthesis the alcohol function of these compounds should be 
protected with the acid-labile dimethoxytrityl (DMT) group. The preparation 
of O-DMT-protected derivatives of 2-aminoethanol, 3-aminopropanol and 6-
aminohexanol is shown in Figure 2. The appropriate chloroalcohols were 
treated first with potassium phthalimide and the resulting phthalimido 
derivatives were reacted with dimethoxytrityl chloride in pyridine. Finally, 
the phthalimido group was removed with hydrazine hydrate giving the 
desired O-DMT-protected amino alcohols (1-3). 
The key compound for the preparation of 5'-O-DMT- 3'-amino-2',3'-
dideoxyuridine and cytosine was 5'-O-DMT-3'-azido-2',3'-dideoxyuridine (6, 
Fig. 3). This compound was prepared from 5'-O-DMT-dU (4) via the 2,3'-
anhydro derivative (5) as previously described for the thymidine derivative 
(17-19). Conversion of the uridine derivative (6) to cytidine (8) was 
performed by activation of position 4 with mesitylensulfonyl chloride, 
formation of the 2-nitrophenyl derivative and displacement of the 2-
nitrophenyl group with ammonia. Afterwards, the amino group of the 
cytidine derivative (8) was protected with the benzoyl group using benzoyl 
chloride in pyridine. During the preparation of this manuscript, a shorter 
route has been described for the preparation of the cytidine derivative (19). 
Finally, 5'-O-DMT-3'-azido-2',3'-dideoxynucleosides (6 and 9) were 
converted to the amino derivatives (7 and 10) using polymeric 
triphenylphosphine (20). 
 
 
 
Figure 2. Preparation of O-DMT-protected derivatives of aminoalcohols 1-
3. (a) potassium phthalimide, DMF, 60 °C; (b) DMT-Cl, pyridine; (c) 
hydrazine hydrate. 
 
 
Preparation of the supports 
Two different types of base-labile linkers were prepared: the (o-
nitrophenyl)ethoxycarbonyl (15) and the fluorenylmethoxycarbonyl (16) 
linkers. The synthesis of the corresponding carboxylic acid derivatives 
needed for incorporation on the polymeric support has been described 
previously (15, 16). We have tried two different routes for the preparation 
of the solid supports having the NPEOC linker (Fig. 4). In the first method, 
1-O-DMT-6-aminohexanol was reacted with a chloroformate derivative of 
the linker molecule, obtaining a molecule that had the amino derivative 
connected to the linker, that was isolated, purified and characterized. In 
order to perform this reaction, the acid carboxylic function of the linker was 
protected as methyl ester. Selective saponification of the methyl ester (15) 
yielded the desired carboxylic acid that was reacted with amino-CPG. This 
route was named the 'solution method' because the reaction of the amino 
derivative with the linker was carried out in solution. In the second method, 
the linker molecule was reacted with the amino-CPG and the resulting 
support was activated either with 1,1'-carbonyldiimidazole (CDI) or with p-
nitrophenyl chloroformate (NPC), followed by reaction with 1-O-DMT-6-
aminohexanol. This route was named the 'solid-phase method' because all 
the steps were performed on the solid support. The efficiency of the 
different methods was estimated by measuring the amount of DMT cation 
released upon acid treatment. The following loadings were obtained for the 
DMT-O-(CH2)6-NH-NPEOC-CPG: 10 mmol/g using the 'solution method'; 20 
mmol/g using the 'solid-phase method' and activation with CDI and 13 mmol 
/g if activation was performed with NPC. From these results and from the 
fact that the 'solid-phase method' was more easy to perform, we selected 
the 'solid-phase method' with CDI-activation for the preparation of the rest 
of the supports. Using this method, the following solid supports were 
prepared: DMT-O-(CH2)6-NH-FMOC-CPG, DMT-O-(CH2)3-NH-NPEOC-CPG, 
DMTO-( CH2)2-NH-NPEOC-CPG, DMT-O-3'-amino-ddCbz- NH-NPEOC-CPG, 
and DMT-O-3'-amino-ddU-NH-NPEOC- CPG. Loadings were in the range of 
15-25 mmol/g except for the 3'-amino-2',3'-dideoxynucleosides that were 5-
6 mmol/g. This difference was assigned to a lower reactivity of the 
secondary amino group of 3'-amino-2',3'-dideoxynucleosides.  
 
 
Figure 3. Preparation of 3’-amino-2',3'-dideoxyuridine and 3'-amino- 2' ,3'-
dideoxycytidine 
 
Oligonucleotide syntheses 
First, hexanucleotide 5'CCGACC-phosphate-(CH2)6- NH2 was prepared 
using DMT-O-(CH2)6-NH-NPEOC-CPG made by the 'solution method' and the 
'solid-phase method'. Syntheses were performed on an automatic DNA 
synthesizer using standard protocols and commercially available cyanoethyl 
phosphoramidites protected with benzoyl and isobutyryl groups. Coupling 
efficiencies were 99%. At the end of the synthesis, supports were treated 
with concentrated ammonia at 55 °C for 16 h. Oligonucleotides were 
purified using COPTM cartridges. After purification, products were analysed 
by analytical HPLC. In both cases, a major peak was obtained that was 
isolated and characterized by MS (see below and Table 1). Overall 
(synthesis and purification) yields were 14% for both supports. We, 
therefore, concluded that both supports are equally effective for the 
preparation of 3-amino tailed oligonucleotides. 
The dodecamer R5 (Table 1) was then prepared using DMT-O-(CH2)6-
NH-NPEOC-CPG produced by activation with CDI and NPC and using DMT-O-
(CH2)6-NH-FMOC- CPG. It has recently been shown that R5 is a powerful 
inhibitor of the proliferation of human cell lines, which have been 
transformed with the mutated Ha-ras gene. 2' After synthesis, deprotection, 
and cartridge purification, HPLC analysis of the product coming from the 
NPEOC linker showed a major component with the expected molecular 
mass. The product obtained from the FMOC linker consisted of a major 
component (50-60%) with the expected retention time and molecular 
weight together with other small components. We tried to characterize the 
more abundant of the side products (retention time 15.6 min, 20-30% of 
total), but we could not obtain the mass spectra. The highest overall yield 
(12%) was obtained from the synthesis using the NPEOC linker prepared by 
activation with CDI (Table 1).  
 
 
 
Figure 4. Outline of the different methods used for the preparation of solid 
supports. Solution method: (a) chloroformate, compound 3, DMAP; (b) 
NaOH, dioxane, methanol; (c) carboxylic acid, DCC, HOBt, LCAA-CPG. 
Solid-phase method: (d) carboxylic acid, DCC, HOBt, LCAA-CPG; (e) CDI or 
NPC; (f) compounds 1-3. 
 
It was observed that a small amount of DMT (10-15% of total) was 
still present on the supports after ammonia treatment. For this reason an 
alternative deprotection protocol was studied. Dodecamer R5 was prepared 
on DMT-O-(CH2)3-NH-NPEOC-CPG. After synthesis, half of the support was 
treated with ammonia and the other half was treated with 0.5 M DBU in 
pyridinc at room temperature for 16 h. The solid support was filtered and 
the filtrates neutralized and concentrated to dryness. Oligonucleotide was 
separated from DBU using a Sephadex column and the fraction containing 
the oligonucleotide was concentrated to dryness and treated with ammonia. 
Although the support coming from the DBU treatment was completely free 
of the DMT (indicating a more efficient release of oligonucleotide), the 
overall yield was lower (9%) than the yield obtained with the standard 
ammonia treatment (14%). This is due to the increased number of 
manipulations that is needed in the DBU-ammonia deprotection protocol.  
 
Table 1. Sequences prepared in this work 
 
 
aType of linker used between solid support and the amino function and 
method used for the preparation of the solid support. NPEOC: (p- 
nitrophenyl) ethoxycarbonyl; FMOC: 9-fluorenylmethoxycarbonyl. CDI: 
activation with carbonyl diimidazole. NPC: activation with p-nitrophenyl 
chloroformate. 
bFinal deprotection. NH3 standard ammonia deprotection. DBU, NH3: two 
step deprotection using 0.5 M DBU in pyridine and after standard ammonia 
treatment. 
cOverall yield after synthesis and HPLC purification. 
dMeasured mass using electrospray. 
eRetention time of the major peaks observed in HPLC (see conditions in 
experimental); n.d.: not determined. 
 
Finally, dodecamer R5 having aminoethanol, 3'-amino- 2',3'-
dideoxycytidine and 3'-amino-2',3'-dideoxyuridine at the 3'-end was 
prepared with the appropriate NPEOC supports prepared by the 'CDI solid-
phase method' and using the standard ammonia deprotection (Fig. 5 and 
Table 1). Moreover, dodecamer R5 carrying a 2-deoxy-1,4-anhydro-D-ribitol 
molecule at the 3' end was prepared for comparative purposes. The 
corresponding support (Fig. 5) was prepared from the appropriate DMT-
protected derivative (22) using the standard succinyl linker. 
 
 
 
 
Figure 5. Structure of solid supports carrying 3'-amino-2',3' 
dideoxynucleosides and 2-deoxy-l,4-anhydro-D-ribitol molecules. 
 
Characterization of modified oligonucleotides by EIMS 
Modified oligonucleotides are usually characterized by enzyme 
digestion and HPLC analysis of the components. Due to exonuclease 
stability and the poor UV-absorption characteristics of some of the amino 
derivatives, this technique is not suitable for the characterization of 3'-
amine-tailed oligonucleotides. The last years have seen important 
developments in MS, especially for protein characterization (23). The high 
sensitivity achieved allows modified oligonucleotides to be routinely 
analysed. We have used a nanoelectrospray device developed in our 
laboratory (24, 25)  to characterize 3'-amine-tailed oligonucleotides. Figure 
6 (A) shows a classical electrospray spectrum with its series of multiply 
charged ions. The peaks can be deconvoluted into a single peak displaying 
the neutral mass of the oligonucleotide [Fig. 6 (B)]. The spectrum was 
obtained using only 15 mg of the oligonucleotide. All oligonucleotides 
discussed in this paper were characterized using this technique (Table 1). 
 
 
Figure 6. MS analysis of oligonucleotide R5 labeled with fluoresceine. The 
figure shows the original electrospray spectrum (A) and the derived 
deconvulation (B) of a synthetic oligonucleotide. The oligonucleotide R5 
labeled with fluoresceine was dissolved to a concentration of 70 pmol/mL in 
water. 0.5 mL of the stock solution were mixed with 10 mL of a 2.5% 
ammonia 1:1, water:methanol solution. One mL of the final solution (3.5 
pmol/mL) was filled into the NanoES source and the spectrum acquired. 
 
 
Table 2. Properties of 3'-amino-modified oligonucleotides: oligonucleotide 
degradation by snake venom phosphodiesterase and melting temperatures 
of duplexes containing 3'-modified oligonucleotides 
 
aMelting experiments were performed in 0.15 M NaCl, 0.05 M Tris-HCl pH 
7.5. Complementary sequence: 3' GTGGCTGCCGCG 5' except for R5CNH2 
that was: 3' GTGGCTGCCGCGG 5'; and for R5UNH2 that was: 3' 
GTGGCTGCCGCGA 5' 
 
Hybridization properties and exonuclease resistance of 3'-amine 
tailed oligonucleotides 
The effect of the modification on the 3'-end on the hybridization 
properties of the oligonucleotides was measured by determination of the 
melting temperatures of DNA-duplexes made of the 3'-modified 
oligonucleotides and their complementary sequences. Melting temperatures 
are shown in Table 2 and they all are similar or slightly higher than the 
melting temperature of the duplex made with unmodified oligonucleotides. 
This indicates that the modifications at the 3'-end that we have prepared 
have very little influence on the hybridization properties of the 
oligonucleotide.  
The stability towards exonuclease degradation of 3' modified 
oligonucleotides was studied by recording the UV absorbance at 260 nm 
during the incubation of oligonucleotides with snake venom 
phosphodiesterase at 37 °C. An increase on the UV absorbance of the 
solution is observed due to the release of the nucleotides from the 
oligonucleotide. From these curves the rate constant can be calculated 
assuming a first-order kinetic. Table 2 shows the values obtained for 
dodecamers R5 having different groups at the 3'-end. Unmodified R5 was 
degraded in 1 h (t 1/2=0.46 h), while 3'-modified oligonucleotides showed a 
higher stability. Oligonucleotides having 3'-amino-2',3'- dideoxynucleosides 
at the 3'-end were approximately 10 times more stable. Similar results were 
described for oligonucleotides having 3'-amino-2',3’-dideoxythymidine (10). 
The dodecamer having the 2-aminoethyl group (R5N2) at the 3'-end was 20 
times more stable and clearly the most stable oligonucleotides were 
dodecamers having 3-aminopropyl (R5N3), 6-aminohexyl (R5N6), and the 
ribitol (R5rib), which were 60 times more stable. The stability found in these 
compounds is in agreement with previous reports (3, 26, 27). 
 
Preparation of oligonucleotide conjugates using 3'-amine tailed 
oligonucleotides  
The use of 3'-amine tailed oligonucleotides for the preparation of 
oligonucleotide conjugates was demonstrated with dodecamers R5N6 and 
R5N3. Reaction of dodecamer having the 3'-aminopropyl at the 3'-end with 
fluorescein-4(5)-carboxamidocaproic acid N-succinimidyl ester at pH 9.0 
yielded the fluoresceine labeled oligonucleotide (70% conversion) that was 
purified (recovery 47%) and characterized by UV-vis and MS. Furthermore, 
reaction of dodecamer having the 6-aminohexyl group with dexamethasone 
succinic acid N-succinimidyl ester (28) yielded the desired oligonucleotide- 
dexamethasone conjugate (65% conversion) that was purified (recovery 
40%) and characterized by MS. 
 
Discussion 
 
There is an increasing interest in oligonucleotides containing different 
amino groups at the 3'-end due to their increased resistance towards 
exonucleases and the special reactivity of the amino function (1, 13-27). 
The applications of these oligonucleotides are dependent on the availability 
of versatile and efficient methodologies to prepare them. In this report we 
have described the preparation of new solid supports that allow the 
synthesis of these Y-modified oligonucleotides. Two different base labile 
linkers have been studied. Best results in terms of degree of 
functionalization, yields, and purity of the products were obtained with 
supports based on the o-nitrophenylethyl group. A support containing the 
fluorenylmethyl group yielded less and more of heterogeneous product. 
Although we could not characterize the observed side products, we believe 
that the FMOC linker is probably not completely stable to the conditions 
encountered during the preparation of the support/during oligonucleotide 
synthesis. The most convenient method for the preparation of the supports 
has been the successive addition of the components (linker, carbonyl group 
and amine derivative) to the support ('solid-phase method'). Unfortunately, 
the coupling of the more hindered 3'-amino-2',3'-dideoxynucleosides is less 
efficient and in these cases supports with low loadings are obtained. 
The preparation of 3'-amino oligonucleotides has been described 
using the standard succinyl linkage (5-8). For that purpose a special 
aminodiol is needed. The first alcohol is needed to attach the derivative to 
the CPG using the standard succinyl group and the second alcohol is needed 
to build the oligonucleotide sequence. The amino group should be protected 
with base-labile groups (FMOC). Also, special phthalimido linkers have been 
designed for the preparation of 3'-amino-tailed oligonucleotides (3-11). 
However, the preparation of these phthalimido derivatives is long and 
phthalimido linkers could be only used for primary amino groups. Other 
linkers such as phosphoramidate (9,10), glycolic and 4-hydroxybutyric (12), 
and dithioethoxycarbonyl (13) need special deprotection protocols to obtain 
the desired 3'-amino oligonucleotide. Compared with existing supports the 
method described here is simple and versatile, because it could be adapted 
to any amino derivative. The NPEOC linker could be easily obtained starting 
from commercially available 4-aminophenethyl alcohol (four steps, 30% 
overall yield) (15). 3'-Modified oligonucleotides could be obtained using 
standard ammonia deprotection conditions or using a nonnucleophilic base 
such as DBU (15). We have observed that the release of the 3'-amino 
oligonucleotide from the NPEOC supports is high (around 85%), but it is not 
completed after an overnight treatment at 55 °C. Use of DBU for the 
deprotection improves the release of oligonucleotide, but increases the 
number of manipulations. Therefore, standard ammonia deprotection is 
preferred. 
An important part of the preparation of modified oligonucleotides is 
the characterization of the products. The control of the DMT release during 
the synthesis and the chromatographic or electrophoresis data are not 
enough to demonstrate the correct incorporation and release of the 3'-
amino oligonucleotide. Enzyme digestion and HPLC analysis of the 
components can lead to wrong interpretations with nuclease resistant 
oligonucleotides. Mass spectrometry using a special nanoelectrospray device 
and quadropole detectors was found to be very suitable for the 
characterization of these modified oligonucleotides. Oligonucleotide 
molecular weights could be determined with high precision with very small 
amounts of material coming from the HPLC purification. 
Oligonucleotide bearing amine derivatives at the 3'-end have been 
shown to hybridize with complementary sequences with the same or slightly 
higher affinity, but they are much more resistant to degradation by snake 
venom phosphodiesterase (3, 26). These properties make them good 
candidates for antisense studies. 
Moreover, due to the singular reactivity of the amino alkyl group, the 
amino modified oligonucleotides are useful intermediates for nonradioactive 
labeling and for the preparation of conjugates with lipids that may facilitate 
cellular uptake. The method described could be adapted not only for the 
incorporation of amino derivatives at the 3'-end of oligonucleotides, but also 
for the incorporation of amino derivatives in peptides and other compounds. 
 
Experimental 
 
General methods 
 
All reactions were carried out in oven-dried glassware, under a 
nitrogen or argon atmosphere. Except when water was present in the 
reaction, at the beginning of the reaction the starting compounds were 
dried by coevaporation with dry solvents. At the end of the reactions, the 
standard work up was as follows: The reaction mixture was concentrated to 
dryness. The residue was dissolved in CH2Cl2 or CHCl3 and washed with the 
following aq solns: 5% NaHCO3 and satd NaCl. The organic phase was dried 
with sodium sulfate and concentrated to dryness. Oligonucleotide syntheses 
were performed on a ABI 392 DNA synthesizer. LCAA-CPG was from CPG 
Inc (New Jersey). Nucleoside (dAbz, dCbz, dGibu, and T) phosphoramidites 
and solutions needed for oligonucleotide synthesis were from Cruachem Ltd 
(Glasgow, Scotland). The remaining reagents were purchased from Aldrich 
Chemical Co (Milwaukee, Wisconsin) and Fluka Chemie AG (Buchs, 
Switzerland). Dry solvents and silica gel for column chromatography (70-
230 mesh) were from S.D.S. (Peypin, France). Analytical TLC was carried 
out on aluminium-backed Merck 60 F254 silica plates. Compounds were 
visualized by UV shadowing and, in the case of compounds containing DMT 
groups, by exposure to hydrochloric acid fumes. HPLC analyses were 
performed on a Waters chromatograph. NMR spectra were recorded on a 
Varian-Geminis FT-200 and a Varian XL-300 spectrometers. Thermal 
dissociation curves, UV spectra and phosphodiesterase degradation curves 
were obtained on a Shimadzu UV-2101 equipped with a pelltier temperature 
controller. 
 
Synthesis of 1-O-dimethoxytrityl-6-amino-1-hexanol (3), 1-O-
dimethoxytrityl-3-amino-1-propanol (2) and 1-O-dimetoxytrityl-2-
amino-1-ethanol (1). 6-Chloro- 1-hexanol (1 g, 7.3 mmol) was dissolved 
in 50 mL of DMF. To the solution 1.5 g (8.1 mmol) of potassium phthalimide 
were added. The mixture was heated at 6°C for 4 h with magnetic stirring. 
The reaction mixture was cooled at room temperature and a white 
precipitate of potassium chloride was observed and filtered out. The solution 
was concentrated to dryness and the residue was treated as described in 
the standard work up obtaining 1.5 g of 6-N-phthatoyl- 6-amino-1-hexanol 
(71% yield). 1H NMR (CDCl3, 200 MHz): d 7.82 (m, 2H), 7.73 (m, 2H), 
3.69-3.62 (2t, 4H), 1.6-1.3 (m, 8H). A similar protocol was used for the 
preparation of 3-N-phthaloyl-3-amino-1-propanol (60% yield) and 2-N-
phthaloyl-2-amino-l-ethanol (63% yield). 1H NMR of these compounds were 
similar to that of aminohexanol derivative with the exception of the signal at 
1.6-1.3 ppm that integrates 2H in the case of 3-N-phthaloyl-3-amino-1-
propanol and does not exist in the case of 2-N-phthaloyl-2-amino-1-
ethanol. 
 
6-N-Phthaloyl-6-amino-1-hexanol (1 g, 4.0 mmol) was dissolved in 20 mL 
of dry pyridine and 1.55 g (4.4 mmol) of DMT-C1 were added. After 16 h of 
magnetic stirring at room temperature, 0.5 mL of methanol was added and 
the mixture was concentrated to dryness. After standard work up, the 
product was purified by column chromatography on silica gel eluting with 
CH2Cl2 obtaining the desired 1-O-DMT-6-N-phthaloyl- 6-amino-1-hexanol. 
Yield: 1.74 g, 78%. 1H NMR (CDCl3, 200 MHz): d 5 7.81 (m, 2H), 7.72 (m, 
2H), 7.4-7.2 (m, 9H), 6.85 (d, 4H), 3.79 (s, 6H), 3.65 (t, 2H), 3.02 (t, 2H), 
1.6-1.3 (m, 8H). A similar protocol was used for the preparation of 1-O-
DMT-3-N-phthaloyl- 3-amino-l-propanol (45% yield) and 1-O-DMT- 2-N-
phthaloyl-2-amino-l-ethanol (60% yield). As described before, 1H NMR of 
these compounds were similar to the aminohexanol derivative with the 
exception of the signal at 1.6-1.3 ppm that integrates 2H in the case of 1-
O-DMT-3-N-phthaloyl-3-amino-1-propanol and does not exist in the case of  
1-O-DMT- 2-N-phthaloyl-2-amino-1-ethanol.  
 
1-O-DMT-6-N-phthaloyl-6-amino-1-hexanol (0.46 g, 0.83 mmol) was 
dissolved in 10 mL of methanol and 0.04 mL of NH2--NH2· H20 were added. 
After 16 h of magnetic stirring at room temperature, the mixture was 
filtered and the solution was concentrated to dryness. After standard work 
up, the product was purified by column chromatography on silica gel eluting 
with a 5-35% methanol gradient in CH2Cl2 obtaining 100 mg (30%) of 1-O-
DMT-6-amino-1-hexanol. TLC (25% methanol in CH2Cl2) Rf 0.25. 1H NMR 
(CDCl3, 200 MHz): 6 7.29 (m, 9H), 6.82 (m, 4H), 4.87 (wide s, 2H), 3.77 
(s, 6H), 3.01 (t, 2H), 2.77 (t, 2H), 1.59 (m, 8H). 1-O-DMT-3-amino-l-
propanol. TLC (25% methanol in CH2Cl2) Rf 0.24. 1H NMR (CDCl3, 200 MHz): 
8 7.29 (m, 9H), 6.82 (m, 4H), 3.77 (s, 6H), 3.16 (t, 2H), 2.88 (t, 2H), 1.86 
(m, 2H). 1-O-DMT-2-amino-1-ethanol. TLC (25% methanol in CH2Cl2) Rf 
0.20. 1H NMR (CDCl3, 200 MHz): d 7.29 (m, 9H), 6.82 (m, 4H), 3.77 (s, 
6H), 2.90 (t, 2H). 
 
5'-O-Dimethoxytrityl-2,3'-anhydro-2'-deoxyuridine (5). Adapted from 
the synthesis of the same thymidine derivative (17), 2.28 g of dU (10 
mmol) were reacted with 3.7 g of DMT-Cl (11 mmol) in pyridine. After 3 h 
at room temperature, the reaction mixture was concentrated to dryness. 
After standard work up 5.24 g (9.87 mmol, 99%) of DMT-dU were obtained. 
13C NMR (CDCl3, 101 MHz): 8 163.7, 158.6, 150.5, 144.2, 140.2, 135.3, 
135.2, 130.0, 128.0, 127.7, 127.0, 113.2, 102.1, 86.7, 86.1, 85.1, 71.4, 
63.0, 55.1, 41.1.  
 
The residue was dissolved in 30 mL of pyridine and the solution was cooled 
with ice. To the solution 2.6 mL of methanesulfonyl chloride (33.2 mmol) 
were added dropwise and the resulting solution was allowed to stir 
overnight at 4 °C. The reaction was quenched by the addition of water (1 
mL) followed by an additional 30 min of stirring. The mixture was poured 
into ice-water (1.5 L) with strong stirring and the resulting product was 
filtered and washed with water. Yield 95%. 
 
The product obtained above (9.5 mmol) was dissolved into a solution 
containing 8.77 g (47.4 mmol) of potassium phthalimide in 140 mL of DMF 
and 40 mL of water. The mixture was heated to 95 °C over 20 min and then 
cooled to room temperature. The mixture was poured slowly to ice-water 
(1.5 L). The white precipitate was filtered and washed with water. Yield 
4.16 g (8.1 mmol, 80%). 13C NMR (CDCl3, 101 MHz): d 170.8, 158.1, 153.3, 
144.1, 139.5, 134.9, 129.5, 127.4, 127.3, 126.4, 112.7, 108.4, 87.1, 86.2, 
83.8, 76.8 (inside CDC3 signals), 61.6, 54.7, 33.0. 
 
5'-O -Dimethoxytrityl-3'-azido-2',3'-dideoxyuridine (6). 
5'-O-DMT-2,3'-anhydro-2'-deoxyuridine (4.16 g, 8.1 mmol) was dissolved in 
DMF and 1.2 g (24.3 mmol) of lithium azide were added. The mixture was 
heated at 135°C for 8 h. The reaction was cooled at room temperature and 
solvents were removed. The residue was purified by silica gel 
chromatography. Yield 3.58 g (6.4 mmol, 79%). 13C NMR (CDCl3, 101 MHz): 
d 163.4, 158.5, 150.2, 144.0, 139.6, 134.9, 129.8, 127.8, 126.9, 113.1, 
102.1, 86.9, 84.6, 83.4, 62.0, 59.4, 55.0, 38.0. 
 
5'-O-Dimethoxytrityl-4-O-(2-nitrophenyl)-3'-azido-2',3'-dideoxyuri-
dine. 5'-O-DMT-3'-azido-2',3'-dideoxuridine (3 g, 5.4 mmol) was dissolved 
in dry CH2Cl2. To a solution of 4.2 mL (30 mmol) of triethylamine, 163 mg 
(1.34 mmol) of DMAP, and 1.76 g (8.08 mmol) of mesitylensulfonyl chloride 
were added.  After 30 min of magnetic stirring at room temperature, 1.49 g 
(10.8 retool) of 2-nitrophenol and 120 mg (1.07 mmol) 1,4 
diazabicyclo[2.2.2]octane were added and the mixture was stirred for 2 h. 
After removal of the solvents and standard work up, the product was 
purified by column chromatography on silica gel eluting with petroleum 
ether:ethyl acetate (1 : 1). Yield 2.69 g (4 mmol, 74%). 13C NMR (CDCl3, 
101 MHz): d 170.4, 158.5, 154.3, 144.7, 144.6, 143.7, 141.3, 134.9, 
134.8, 134.6, 129.7, 127.8, 126.9, 126.4, 125.6, 125.2, 113.1, 94.2, 87.1, 
86.9, 86.3, 83.8, 61.3, 58.4, 54.9, 38.5. 
 
5'-O-Dimethoxytrityl-3'-azido-2',3'-dideoxycytidine (8). 5 '-O-DMT-4-
O-( 2-nitrophenyl )- 3 '-azido- 2',3 '-dideoxyuridine (2.3 g, 3.4 mmol) was 
dissolved in dioxane and the solution was installed on a stainless steel 
bomb. Ammonia was distilled on the bomb and the reaction was heated at 
60 °C for 2 days. The bomb was cooled to room temperature and ammonia 
was released slowly. The resulting mixture was transferred to a round-
bottom flask together with successive washings with a 20% methanol 
solution in CH2Cl2. The product was purified by silica gel. Yield: 1.6 g (2.9 
mmol, 85%). 13C NMR (CDCl3, 101 MHz): d 165.9, 158.4, 155.7, 144.2, 
139.7, 135.0, 129.8, 127.7, 126.7, 113.0, 94.8, 86.6, 85.3, 83.1, 61.9, 
59.2, 54.9, 38.3. 
 
5'-O-Dimethoxytrityi-N4-benzoyl.3 '-azido-2',3'-dideoxycytidine (9). 
5'-O-DMT-3'-azido-2',3'-dideoxycytidine (1.6 g, 2.9 mmol) was dissolved in 
20 mL of pyridine and 0.39 mL (3.77 mmol) of benzoyl chloride were 
added. After 1 h of magnetic stirring at room temperature, the solvents 
were concentrated. After standard work up, the product was purified on 
silica gel eluting with a 0 to 5% methanol gradient in CH2Cl2. Yield 90%. 13C 
NMR (CDCl3, 101 MHz): d 166.4, 162.3, 158.5, 154.5, 144.3, 143.8, 130.5, 
134.9, 132.9, 129.8, 129.7, 128.7, 127.8, 127.5, 127.0, 113.2, 96.4, 87.0, 
86.4, 83.9, 61.4, 58.4, 55.0, 38.8. 
 
5'-O-DimethoxytrityI-N4-benzoyl-3'-amino-2',3'-dideoxycytidine 
(10) and 5'-O-dimethoxytrityl-3'-amino-2',3'- dideoxyuridine (7). 
DMT-3'-azido-dideoxynucleosides (6 and 9, 0.2 mmol) were treated with 
polymer supported triphenylphosphine (Fluka, 0.33 g loading 3 mmol per g) 
as described (20). 
 
Preparation of the solid support loaded with the 6- O-DMT-6-
hydroxyhexylaminocarbonyloxy-o-nitrophenylethyl group using the 
solution method  
 
Preparation of 4-[2-(6-O-dimethoxytrityl-6-hydroxy- 1-hexylamino) 
carbonyloxyethyl] -3-nitrobenzoate methyl ester. 1-O-DMT-6-amino-l-
hexanol (105 mg, 0.25 mmol) and DMAP (46 mg, 0.34 mmol) were 
dissolved in 10 mL of dry CH2Cl2 and the mixture was cooled with an ice-
bath. To the solution 104 mg (0.34 mmol) of 2-[4-(methoxycarbonyl)-2-
nitrophenyl]ethyl chloroformate (15) was added. After 30 min of magnetic 
stirring at 0 °C, the solution was left for 1 h at room temperature. The 
solution was concentrated to dryness and the residue was purified by 
column chromatography on silica gel eluting with a 50-80% CH2Cl2 gradient 
in hexane. Yield 80 mg (40%). TLC (CH2Cl2:hexane, 1:1) Rf 0.5. 1H NMR 
(CDCl3, 200 MHz): d 8.60 (s, 1H), 7.8 (d, 1H), 7.46 (d, 1H), 7.29 (m, 9H), 
6.80 (m, 4H), 4.46 (t, 2H), 3.95 (s, 3H), 3.77 (s, 6H), 3.33 (t, 2H), 2.80 (t, 
2H), 1.6-1.2 (m, 6H). 
 
Hydrolysis of the methyl ester. 4-[2-(6-O-DMT-6- hydroxy-l-
hexylamino)carbonyloxyethyl]-3-nitrobenzoate methyl ester (50 mg, 0.063 
mmol) was dissolved in 3.2 mL of acetonitrile and 6.3 mL of a 0.05 M NaOH 
solution in water:dioxane (1 : 1) was added. After 5 min of magnetic 
stirring at room temperature the solution was neutralized by addition of 
0.018 mL (0.31 mmol) of acetic acid and concentrated to dryness. The 
residue was dissolved in 30 mL of a 5% methanol solution in CH2Cl2 and the 
organic solution washed twice with 30 mL of a 10% citric acid soln. The 
organic phase was dried and concentrated to dryness to yield 40 mg of the 
desired handle (80% yield). TLC (10% methanol: CH2Cl2) Rf 0.45. The 
proton NMR is identical to the starting material except for the absence of 
the signal at 3.95 ppm (methyl ester). 
 
Preparation of the solid support. The product obtained was used directly 
for the functionalization of the CPG solid support. The handle acid (40 mg, 
0.05 mmol) was dissolved in DMF together with 6.9 mg of HOBt and 13.2 
mg of DCC. After 10 min on ice the mixture was added to 200 mg of long 
amino alkyl CPG (71 mmol/g). The mixture was left at room temperature 
overnight with occasional mixing. The suspension was filtered and washed 
with DMF and acetonitrile. Unreacted amino groups were acetylated by 
treatment of the support with a 10% acetic anhydride solution in pyridine 
for 30 min. Finally, the support was exhaustively washed with acetonitrile 
and dried. Loading was 10 mmol of DMT groups per g. 
 
Preparation of solid supports with amino derivatives connected 
through base-labile linkers using the solid phase method 
 
(a) Functionalization of CPG with the 4-(2-hydroxyethyl)- 3-
nitrobenzoic acid and the N-[9-(hydroxymethyl)- 2-fluorenyl] 
succinamic acid. 4-(2-Hydroxyethyl)-3-nitrobenzoic acid (15) (12 mg, 
0.057 mmol), HOBt (9.6 mg, 0.057 mmol), and DCC (11.7 mg, 0.057 
mmol) were dissolved in 5 mL of DMF and the solution was kept on ice for 
10 rain. The resulting mixture was added to 0.4 g of long aminoalkyl CPG 
(71 mmol/g). The reaction was left at room temperature with occasional 
mixing. After 16 h the support gave a negative ninhydrin test and the 
suspension was filtered. The resulting support was washed with DMF, 
CH2Cl2, and acetonitrile, and dried. A similar protocol was used for the 
incorporation of N-[9-(hydroxymethyl)-2-fluorenyl] succinamic acid (16). 
 
(b) Activation of the hydroxyl function of the solid supports 
functionalized with the o-nitrophenylethanol and the 9-
fluorenylmethanol groups 
 
(I) Using 1,1-carbonyl diimidazole. CPG (0.1 g) loaded with the 2-(o-
nitrophenyl)ethanol or the 9-fluorenylmethanol groups were treated with a 
solution of 16.2 mg of CDI in 1 mL of acetonitrile. After 4 h at room 
temperature the supports were filtered and washed with dry acetonitrile and 
dried. 
 
(II) Using p-nitrophenyl chloroformate. CPG (0.2 g) loaded with the o-
nitrophenylethanol group were treated with a solution of 86.2 mg (0.42 
mmol) of NPC in 1 mL of acetonitrile. After 16 h at room temperature the 
supports were filtered and washed with dry acetonitrile and dried. 
 
(c) Functionalization of solid supports with the amino 
derivatives. Activated solid supports (0.1 g) were treated with a solution of 
0.07 mmol (30 mg) of 1-O-DMT-6-amino-l-hexanol dissolved in 1 mL of 
acetonitrile. After 16 h at room temperature the suspensions were filtered 
and the solid supports washed with acetonitrile, CH2Cl2 and acetonitrile, and 
dried. The resulting solid supports were treated with 2 mL of a 5% n-
butylamine solution in acetonitrile in order to block the activated hydroxyl 
groups that did not react with the desired amino derivative. The solid 
supports were washed with acetonitrile and treated with a 10% acetic 
anhydride solution in pyridine for 30 min. This treatment was designed to 
block hydroxyl groups that were not activated with CDI or NPC. After 
capping the solid supports were washed extensively with acetonitrile and 
dried. Functionalization of the supports were analyzed by measurement of 
the absorbance of the DMT cation released when a known amount of 
support was treated with acid solutions. Loadings were as follows: DMT-O-
(CH2)6-NHNPEOC- CPG via activation with CDI: 20 mmol/g; the same 
support obtained by activation with NPC: 13 mmol/g. DMT-O-(CH2)6-NH-
FMOC-CPG via activation with CDI 14 mmol/g. 
 
The rest of the supports containing other amino derivatives were prepared 
using the NPEOC linker and the activation with CDI. Loadings were as 
follows: DMT-O-(CH2)3-NH-NPEOC-CPG: 20 mmol/g; DMTO-(CH2)2-NH-
NPEOC-CPG: 23 mmol/g; 5'-O-DMT- 3'-amino-ddCbz-NH-NPEOC-CPG: 6 
mmol/g and 5'-O-DMT-3'-amino-ddU-NH-NPEOC-CPG: 5 mmol/g. 
 
Oligonucleotide synthesis and purification 
Sequences A: 5'CACCGACGGCGC3' and B: 5'CCGACC3’ were assembled 
using the solid supports and the appropriate protected nucleoside 
phosphoramidites on an automatic DNA synthesizer. The standard 1 mmol 
scale synthesis cycle was used. In all cases the last DMT group was left to 
help purification. Coupling efficiencies were 99%.  
 
Deprotection of oligonucleotide supports were as follows: (a) standard 
deprotection; the supports were treated with 2 mL of a concentrated 
ammonia solution (32%) at 55 °C for 16 h. The solution was filtered and 
the support washed with water. The combined filtrates were used directly if 
purification was performed using COPTM cartridges; and (b) two-steps 
deprotection: the supports were treated with a 0.5 M DBU solution in 
pyridine (2 mL) at room temperature for 16 h. The support was washed 
with pyridine and water. The combined filtrates were neutralized with acetic 
acid (0.06 mL) and concentrated to dryness. The residue was desalted with 
Sephadex G-10 eluted with 20 mM triethylammonium acetate pH 7.5. The 
fractions containing the oligonucleotide were combined and concentrated to 
dryness. The residue was treated with 2 mL of a concentrated ammonia 
solution at 55 °C for 16 h and proceeded as described for the standard 
deprotection. 
 
Oligonucleotides with the DMT group at the 5'-end were purified using 
COPTM cartridges (Cruachem Ltd, Scotland) following the instructions of the 
manufacturers. Further purification was achieved by reversed phase HPLC. 
HPLC conditions were as follows: Column: Nucleosil 120C18 (200 ×4 mm), 
flow rate 1 mL/min, a 20 min linear gradient from 2 to 25% acetonitrile 
over 20 mM aq triethylammonium acetate. In all cases a major peak was 
observed except in the synthesis of 5'CACCGACGGCGC-phosphate-(CH2)6- 
NH2 prepared using the FMOC solid support in where some other products 
were observed. Characterization by mass spectrometry and yields are 
shown in Table 1. 
 
Melting studies 
Solutions of equimolar amounts of oligonucleotide A (5'CACCGACGGCGC3') 
and the appropriate complementary sequence (3'GTGGCTGCCGCG5', 
3'GTGGCTGCCGCGG 5' and 3'GTGGCTGCCGCGA5') were mixed in 0.15 M 
NaCl 0.05 M Tris-HC1 pH 7.5 buffer. The solutions were heated at 80 °C and 
allowed to cool slowly to room temperature and samples were kept in the 
refrigerator overnight. UV absorption spectra and melting experiments 
(absorbance versus temperature) were recorded in 1 cm path-length cells 
using a spectrophotometer, which has a temperature controller with a 
programmed temperature increase of 0.5 ° min-1. Melts were run on duplex 
concentration of 4 mM at 260 nm. 
 
Phosphodiesterase degradation studies 
0.4 0D units at 260 nm (0.013 mg) of each 3'-modified dodecamers were 
dissolved in 1 mL of a buffer containing 0.1 M Tris-HC1 pH 8.6, 0.1 M NaCl, 
and 14 mM MgCl2. To the solution 1 mL of a commercial solution of snake 
venom phosphodiesterase (Boehringer Mannheim) was added and the 
sample was maintained at 37 °C. The increase on the absorbance at 260 
nm was measured every 30 s for at least 6 h. The absorption versus time 
curve of the digestion was plotted from which half-life was calculated 
assuming a first-order kinetic. 
 
Preparation of oligonucleotide-dexamethasone and fluoresceine 
conjugates.  
 
Dexamethasone. Three OD units at 260 nm (approximately 0.1 mg) of 
dodecamer R5N6 were dissolved in 0.3 mL of water. Then 0.2 mL of 1 M 
sodium carbonate buffer pH 9.0 were added together with a solution made 
with 5 mg of dexamethasone hemisuccinamic acid N-hydroxysuccinimide 
ester (28) and 0.5 mL of DMF. After 30 min at room temperature, the 
solution was concentrated to dryness and the residue was dissolved in 
water and filtered. The resulting solution was injected into the HPLC. HPLC 
conditions were the same as described in oligonucleotide purification with 
the exception of the gradient. In this case a 40 min gradient from 2 to 45% 
acetonitrile was used. The retention time of dexamethasone dodecamer was 
21.3 min (65% of the total area). Yield: 1.2 0D units (40%). MS: M + 2Na 
4316.0, expected M 4273. 
 
Fluoresceine. Three OD units at 260 nm (approximately 0.1 mg) of 
dodecamer R5N3 were dissolved in 0.3 mL of 0.5 M sodium carbonate 
buffer pH 9.0. To this solution was added 3 mg of fluorescein-4(5)-
carboxamido caproic acid N-hydroxysuccinimide ester (Fluka) dissolved in 
0.3 mL of DMF. After 6 h at room temperature, the solution was 
concentrated to dryness and the residue was purified by Sephadex G-10 
and HPLC as described before. The conversion to the fluoresceine product 
was 70% as judged by the area of the peaks on the HPLC chromatogram. 
Yield: 1.40D (47%). HPLC (40 min gradient from 2% to 40% acetonitrile) 
retention time 21.5 min. UV max (water): 255 and 494 nm. MS: M 4224.0, 
expected M 4224.5. 
 
Mass spectrometry analysis of oligonucleotides 
The MS were acquired on an API III triple quadrupole mass spectrometer  
cell (Perkin-Elmer Sciex Instruments, Thornhill, Canada) and a 
NanoElectrospray ion source developed in our group (24, 25). 
Needles were prepared as previously described (25). They were typically 
filled with 0.5-1 mL of sample solution with analyte concentration of 1-5 
pmoles/ mL in 50% methanol and 2-5% ammonia. 
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